Difacta (Emtricitabine + Dolutegravir + Tenofivir Alafemide)

Emtricitabine + Dolutegravir + Tenofovir Alafenamide is a potent antiretroviral combination therapy designed for individuals managing HIV-1 infection. This triple-drug formulation works synergistically to suppress viral replication and support immune function.

The standard dose is one tablet taken orally once daily with or without food, making adherence straightforward for long-term treatment success.

Common side effects may include nausea, diarrhea, headache, and fatigue, typically mild and manageable. Some patients experience dizziness or sleep disturbances. Serious but rare effects can involve liver complications or kidney concerns, requiring regular monitoring. Most side effects diminish as your body adjusts to the medication.

This combination represents a modern approach to HIV management, offering efficacy with a convenient once-daily dosing schedule. The integrase inhibitor component provides rapid viral suppression, while the nucleoside reverse transcriptase inhibitors deliver sustained protection.

Consistent daily use as prescribed maximizes therapeutic benefits and helps prevent drug resistance, supporting your path toward undetectable viral loads and improved quality of life.